Background: The emergence of infectious diseases and its resistance to approved drugs
is a global threat to human health. The incidence of infectious diseases is increasing day by day
and expected to rise exponentially in next 2 decades. Thus, there is a need for new treatment
modalities for the treatment of microbial infections.
Methods: Thus, in the current investigation, we have explored the existing drugs [metformin
(Anti-diabetic), propranolol (Anti-hypertensive) and amitriptyline (antidepressant)] for treatment
of infectious diseases.
Results: An in-silico result of current investigation has shown the good interaction of metformin,
propranolol, and amitriptyline towards various targets (Beta-lactamase, Penicillin-binding
proteins, Staphylokinase protein, Oxidoreductase protein, etc.) of gram positive and gram negative
bacteria as that of internal ligand. Further, in-vitro results have shown that the antibacterial
activity of metformin, propranolol, and amitriptyline against Bacillus pumilus, Pseudomonas
aeruginosa and Staphylococcus aureus.
Conclusion: The parameters such as Microtiter assay: percentage growth retardation and bacterial
growth kinetics, Minimum inhibitory concentration (MIC), Post-antibiotic assay and Biofilm
formation have indicated the antibacterial potential of metformin, propranolol, and amitriptyline.
However, before starting a clinical trial, complete safety and efficacy profile of drugs in the
treatment of infectious diseases should be investigated.